Kalbe Farma Tbk PT (KLBF) - Total Assets
Based on the latest financial reports, Kalbe Farma Tbk PT (KLBF) holds total assets worth Rp29.51 Trillion IDR (≈ $1.73 Billion USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Kalbe Farma Tbk PT (KLBF) cash flow to debt to assess how comfortably operating cash covers total debt obligations.
Kalbe Farma Tbk PT - Total Assets Trend (2000–2024)
This chart illustrates how Kalbe Farma Tbk PT's total assets have evolved over time, based on quarterly financial data. See KLBF net asset value for net asset value and shareholders' equity analysis.
Kalbe Farma Tbk PT - Asset Composition Analysis
Current Asset Composition (December 2024)
Kalbe Farma Tbk PT's total assets of Rp29.51 Trillion consist of 58.4% current assets and 41.6% non-current assets.
| Asset Category | Amount (IDR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rp3.09 Trillion | 16.1% |
| Accounts Receivable | Rp5.01 Trillion | 17.0% |
| Inventory | Rp6.50 Trillion | 22.1% |
| Property, Plant & Equipment | Rp8.78 Trillion | 29.8% |
| Intangible Assets | Rp1.74 Trillion | 5.9% |
| Goodwill | Rp615.45 Billion | 2.1% |
Asset Composition Trend (2000–2024)
This chart illustrates how Kalbe Farma Tbk PT's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see KLBF market cap.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Kalbe Farma Tbk PT's current assets represent 58.4% of total assets in 2024, an increase from 0.0% in 2000.
- Cash Position: Cash and equivalents constituted 16.1% of total assets in 2024, up from 7.4% in 2000.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 7.0% of total assets, an increase from 6.0% in 2000.
- Asset Diversification: The largest asset category is property, plant & equipment at 29.8% of total assets.
Kalbe Farma Tbk PT Competitors by Total Assets
Key competitors of Kalbe Farma Tbk PT based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Roche Holding AG
SW:ROG
|
Switzerland | CHF100.70 Billion |
|
Novo Nordisk A/S
CO:NOVO-B
|
Denmark | Dkr542.90 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
|
AstraZeneca PLC
NYSE:AZN
|
USA | $114.02 Billion |
|
AstraZeneca PLC
NASDAQ:AZN
|
USA | $114.02 Billion |
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Pfizer Limited
NSE:PFIZER
|
India | Rs49.22 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.66 Billion |
Kalbe Farma Tbk PT - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 3.78 | 3.96 | 3.83 |
| Quick Ratio | 2.30 | 2.43 | 2.60 |
| Cash Ratio | 0.37 | 0.00 | 0.00 |
| Working Capital | Rp12.92 Trillion | Rp12.62 Trillion | Rp9.53 Trillion |
Kalbe Farma Tbk PT - Advanced Valuation Insights
This section examines the relationship between Kalbe Farma Tbk PT's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.39 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 8.8% |
| Total Assets | Rp29.43 Trillion |
| Market Capitalization | $1.93 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Kalbe Farma Tbk PT's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Kalbe Farma Tbk PT's assets grew by 8.8% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Kalbe Farma Tbk PT (2000–2024)
The table below shows the annual total assets of Kalbe Farma Tbk PT from 2000 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | Rp29.43 Trillion ≈ $1.72 Billion |
+8.77% |
| 2023-12-31 | Rp27.06 Trillion ≈ $1.59 Billion |
-0.67% |
| 2022-12-31 | Rp27.24 Trillion ≈ $1.60 Billion |
+6.14% |
| 2021-12-31 | Rp25.67 Trillion ≈ $1.50 Billion |
+13.75% |
| 2020-12-31 | Rp22.56 Trillion ≈ $1.32 Billion |
+11.35% |
| 2019-12-31 | Rp20.26 Trillion ≈ $1.19 Billion |
+11.67% |
| 2018-12-31 | Rp18.15 Trillion ≈ $1.06 Billion |
+9.21% |
| 2017-12-31 | Rp16.62 Trillion ≈ $973.65 Million |
+9.13% |
| 2016-12-31 | Rp15.23 Trillion ≈ $892.18 Million |
+11.17% |
| 2015-12-31 | Rp13.70 Trillion ≈ $802.56 Million |
+10.23% |
| 2014-12-31 | Rp12.43 Trillion ≈ $728.06 Million |
+9.81% |
| 2013-12-31 | Rp11.32 Trillion ≈ $663.02 Million |
+20.14% |
| 2012-12-31 | Rp9.42 Trillion ≈ $551.85 Million |
+13.82% |
| 2011-12-31 | Rp8.27 Trillion ≈ $484.86 Million |
+17.66% |
| 2010-12-31 | Rp7.03 Trillion ≈ $412.08 Million |
+8.49% |
| 2009-12-31 | Rp6.48 Trillion ≈ $379.85 Million |
+13.65% |
| 2008-12-31 | Rp5.70 Trillion ≈ $334.22 Million |
+11.01% |
| 2007-12-31 | Rp5.14 Trillion ≈ $301.08 Million |
+11.11% |
| 2006-12-31 | Rp4.62 Trillion ≈ $270.98 Million |
-0.19% |
| 2005-12-31 | Rp4.63 Trillion ≈ $271.50 Million |
+53.58% |
| 2004-12-31 | Rp3.02 Trillion ≈ $176.78 Million |
+23.22% |
| 2003-12-31 | Rp2.45 Trillion ≈ $143.47 Million |
+21.48% |
| 2002-12-31 | Rp2.02 Trillion ≈ $118.10 Million |
+7.36% |
| 2001-12-31 | Rp1.88 Trillion ≈ $110.00 Million |
+6.80% |
| 2000-12-31 | Rp1.76 Trillion ≈ $103.00 Million |
-- |
About Kalbe Farma Tbk PT
PT Kalbe Farma Tbk., together with its subsidiaries, develops, manufactures, and trades in pharmaceutical products in Indonesia. The company operates through Prescription Pharmaceuticals; Consumer Health; Nutritionals; and Distribution and Logistic segments. The company provides prescription/ethical; consumer health; nutritionals; distribution and logistics; health services; medical devices; biop… Read more